Table 1. Presenting features of patients with CML at diagnosis and sampling.

Patient	Age	Sex	Diagnosis time (month/year)	Sampling time (month/year)	Treatment prior tosampling	Immature Neutrophils (%)	Diagnosis	Ph+ (%)	BCR-ABL1a
Isolation of MVs
1	32	M	8 / 2011	9 / 2011	Noneb	93	CML-CPc	98	+
2	26	F	8 / 2011	9 / 2011	None	91	CML-CP	95	+
3	14	F	1 / 2011	11 / 2011	Hud	90	CML-CP	NAe	+
4	19	M	1 / 2011	1 / 2012	Hu	97	CML-CP	100	+
5	32	F	12 / 2011	1 / 2012	None	99	CML-CP	100	0.411
6	35	M	12 / 2011	1 / 2012	None	93	CML-CP	100	0.451
7	42	M	2 / 2012	3 / 2012	None	56	CML-CP	78	0.209
8	13	F	3 / 2012	3 / 2012	None	94	CML-CP	100	+
9	45	F	3 / 2012	3 / 2012	None	80	CML-CP	100	+
10	19	M	2 / 2012	4 / 2012	Hu	94	CML-CP	100	+
11	40	M	3 / 2012	4 / 2012	None	99	CML-CP	100	+
Isolation of BM-MSCs
1	41	M	3 / 2012	3 / 2012	None	98	CML-CP	100	+
2	46	F	4 / 2012	4 / 2012	None	96	CML-CP	97	+
3	29	M	4 / 2012	4 / 2012	None	98	CML-CP	100	+
4	22	F	3 / 2017	3 / 2017	None	91	CML-CP	97	0.653
5	36	F	3 / 2017	3 / 2017	None	95	CML-CP	96	0.524
6	43	M	4 / 2017	4 / 2017	None	96	CML-CP	98	0.412

^aBCR-ABL gene was detected for all of the patients by reverse transcription PCR (+/−) or real-time quantitative PCR.

^bNone means no treatments prior to diagnosis.

^cCML-CP, chronic phase of CML.

^dHu stands for treatment of oral hydroxyurea.

^eNo data available.